Soligenix Inc. (NASDAQ:SNGX) has been assigned a $5.00 price target by research analysts at Maxim Group in a research report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 141.55% from the company’s previous close.

Separately, HC Wainwright initiated coverage on shares of Soligenix in a report on Monday, July 17th. They issued a “buy” rating for the company.

Soligenix (NASDAQ:SNGX) traded up 0.49% during mid-day trading on Tuesday, hitting $2.07. 41,919 shares of the stock were exchanged. Soligenix has a one year low of $1.90 and a one year high of $5.25. The company has a 50-day moving average price of $2.21 and a 200-day moving average price of $2.37. The company’s market cap is $11.85 million.

Soligenix (NASDAQ:SNGX) last released its earnings results on Friday, August 11th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.09). Soligenix had a negative return on equity of 129.88% and a negative net margin of 86.15%. The firm had revenue of $1.00 million during the quarter, compared to analyst estimates of $1.43 million. Analysts forecast that Soligenix will post ($1.48) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/soligenix-inc-sngx-given-a-5-00-price-target-by-maxim-group-analysts.html.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.